Clinical Efficacy and Safety of Anlotinib Combined with Immune Checkpoint Inhibitors in the Treatment of Advanced Squamous Cell Lung Cancer: A Retrospective Single-Center Study in China
The findings of this study confirmed the effectiveness and safety of anlotinib and ICIs for advanced SqCLC.
Authors
- Bin Xu (ORCID: https://orcid.org/0000-0001-5511-8055)
- Li Li (ORCID: https://orcid.org/0000-0002-3183-445X)
- Yu‐Chao Wang (ORCID: https://orcid.org/0000-0002-1574-1691)
- Chunhua Xu (ORCID: https://orcid.org/0000-0003-4007-7566)
Institutions
- Nanjing Brain Hospital (CN)
- Nanjing Chest Hospital (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Current Cancer Drug Targets
- Published
- 2024-11-07
- DOI
- https://doi.org/10.2174/0115680096299425240925073611
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00